Barclays Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $85

Benzinga Newsdesk www.benzinga.com Negative 85.6%

Neg 85.6% Neu 0% Pos 0%

Barclays analyst Eliana Merle maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $90 to $85.